Literature DB >> 24761842

Triple negative breast cancer.

Idil Cetin1, Mehmet Topcul.   

Abstract

Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed. This mini-review focuses on discovery of new targets and drugs which might offer new hope for TNBC patients.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24761842     DOI： 10.7314/apjcp.2014.15.6.2427

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN： 1513-7368


  17 in total

1.  MiR-214-3p regulates the viability, invasion, migration and EMT of TNBC cells by targeting ST6GAL1.

Authors:  Yun Tao; Zhijing Zhao; Junfeng Ma; Liying Dong; Ying Liang; Siqi Li; Ying Mao; Yan Li; Yi Zhang
Journal:  Cytotechnology       Date:  2019-11-08       Impact factor: 2.058

2.  Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes.

Authors:  Rebecca Reed Moody; Miao-Chia Lo; Jennifer L Meagher; Chang-Ching Lin; Nicholas O Stevers; Samantha L Tinsley; Inkyung Jung; Aleksas Matvekas; Jeanne A Stuckey; Duxin Sun
Journal:  J Biol Chem       Date:  2017-12-20       Impact factor: 5.157

Review 3.  Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.

Authors:  Citra Dewi; Adryan Fristiohady; Riezki Amalia; Nur Kusaira Khairul Ikram; Sugeng Ibrahim; Muchtaridi Muchtaridi
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

4.  Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.

Authors:  Ahmad Salahuddin; Heba Ghanem; Gamal A Omran; Maged Wasfy Helmy
Journal:  Med Oncol       Date:  2022-07-18       Impact factor: 3.738

5.  Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model.

Authors:  F Yang; M Hu; Q Lei; Y Xia; Y Zhu; X Song; Y Li; H Jie; C Liu; Y Xiong; Z Zuo; A Zeng; Y Li; L Yu; G Shen; D Wang; Y Xie; T Ye; Y Wei
Journal:  Cell Death Dis       Date:  2015-03-26       Impact factor: 8.469

6.  Interaction of MRE11 and Clinicopathologic Characteristics in Recurrence of Breast Cancer: Individual and Cumulated Receiver Operating Characteristic Analyses.

Authors:  Cheng-Hong Yang; Sin-Hua Moi; Li-Yeh Chuang; Shyng-Shiou F Yuan; Ming-Feng Hou; Yi-Chen Lee; Hsueh-Wei Chang
Journal:  Biomed Res Int       Date:  2017-01-04       Impact factor: 3.411

7.  Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.

Authors:  Junbin Wang; Rongsheng Zheng; Zishu Wang; Yan Yang; Mingxi Wang; Weiyan Zou
Journal:  Med Sci Monit       Date:  2017-09-28

8.  Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.

Authors:  Seung Eun Lee; Ha Young Park; So Dug Lim; Hye Seung Han; Young Bum Yoo; Wan Seop Kim
Journal:  J Breast Cancer       Date:  2020-06-01       Impact factor: 3.588

9.  High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.

Authors:  Yuan-Feng Lin; Ing-Jy Tseng; Chih-Jung Kuo; Hui-Yu Lin; I-Jen Chiu; Hui-Wen Chiu
Journal:  J Cell Mol Med       Date:  2018-02-01       Impact factor: 5.310

10.  Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients.

Authors:  Hae Min Jeong; Ryong Nam Kim; Mi Jeong Kwon; Ensel Oh; Jinil Han; Se Kyung Lee; Jong-Sun Choi; Sara Park; Seok Jin Nam; Gyung Yup Gong; Jin Wu Nam; Doo Ho Choi; Hannah Lee; Byung-Ho Nam; Yoon-La Choi; Young Kee Shin
Journal:  Oncotarget       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.